AI Rare Platform
​
Our approach to rare diseases therapy started from the Search & Match model, initially developed in 2001 by Mondobiotech's founders, and was honored with the WEF Technology Pioneer Award.
Today, MondoRare has advanced this groundbreaking model by integrating state-of-the-art AI technology.
Our AI Rare platform enhances the accuracy and efficiency of identifying potential therapies, ensuring rapid progression to clinical application.
Examples of Founders' past successes​​
​
"Lung Rx LLC, A Subsidiary Of United Therapeutics Corporation, And Mondobiotech Announce Today a Global Strategic Partnership Agreement for the Development Of Aviptadil Platform" ​
​
​​
​
"Biogen Idec Licenses PAH Drug From MondoBiotech"
​​
​
"Licensing agreement for interferon gamma with InterMune. Sold to Roche in 2014 for more than $8,3 billion"
​
​​​
“mondoBIOTECH holding AG (SIX:RARE): United States FDA grants mondoBIOTECH’s Medicinal Product Candidate DasKloster0210 the Orphan Drug Designation for the treatment of Chronic Beryllium Disease.”
​
​
“European Commission grants mondoBIOTECH’s product Aviptadil the Orphan Designation for treating ALI”
​​​​​​​​​​
​
More...
​
​
​
​
​
​
